202 related articles for article (PubMed ID: 17850236)
1. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients.
Konstandin MH; Sommerer C; Doesch A; Zeier M; Meuer SC; Katus HA; Dengler TJ; Giese T
Transpl Int; 2007 Dec; 20(12):1036-43. PubMed ID: 17850236
[TBL] [Abstract][Full Text] [Related]
2. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression.
Sommerer C; Giese T; Schmidt J; Meuer S; Zeier M
Transplantation; 2008 Jan; 85(1):15-21. PubMed ID: 18192906
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients.
Sommerer C; Hartschuh W; Enk A; Meuer S; Zeier M; Giese T
Clin Transplant; 2008; 22(5):549-54. PubMed ID: 18394001
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A.
Giese T; Zeier M; Schemmer P; Uhl W; Schoels M; Dengler T; Buechler M; Meuer S
Transplantation; 2004 Feb; 77(3):339-44. PubMed ID: 14966405
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients.
Billing H; Giese T; Sommerer C; Zeier M; Feneberg R; Meuer S; Tönshoff B
Pediatr Transplant; 2010 Nov; 14(7):844-51. PubMed ID: 20602720
[TBL] [Abstract][Full Text] [Related]
6. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
7. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
Sommerer C; Konstandin M; Dengler T; Schmidt J; Meuer S; Zeier M; Giese T
Transplantation; 2006 Nov; 82(10):1280-5. PubMed ID: 17130775
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of nuclear factor of activated T-cell-regulated gene expression in de novo and long-term liver transplant recipients treated with cyclosporine a.
Herden U; Kromminga A; Hagel C; Hartleb J; Nashan B; Sterneck M; Fischer L
Ther Drug Monit; 2011 Apr; 33(2):185-91. PubMed ID: 21383649
[TBL] [Abstract][Full Text] [Related]
10. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Transpl Infect Dis; 2014 Jun; 16(3):379-86. PubMed ID: 24666466
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
Sommerer C; Schnitzler P; Meuer S; Zeier M; Giese T
Ther Drug Monit; 2011 Dec; 33(6):694-8. PubMed ID: 22105585
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
Barnard JB; Thekkudan J; Richardson S; Bittar MN; Martyszczuck R; Hasan J; Khasati N; Keevil B; Yonan N
J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic monitoring by residual NFAT-regulated gene expression in stable pediatric liver transplant recipients.
Billing H; Breil T; Schmidt J; Tönshoff B; Schmitt CP; Giese T; Engelmann G
Pediatr Transplant; 2012 Mar; 16(2):187-94. PubMed ID: 22360403
[TBL] [Abstract][Full Text] [Related]
16. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
17. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
Caforio AL; Tona F; Piaserico S; Gambino A; Feltrin G; Fortina AB; Angelini A; Alaibac M; Bontorin M; Calzolari D; Peserico A; Thiene G; Iliceto S; Gerosa G
Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
[TBL] [Abstract][Full Text] [Related]
18. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and C2 cyclosporin monitoring in maintenance renal transplant recipients: 1 year follow-up study.
Marcén R; Villafruela JJ; Pascual J; Teruel JL; Ocaña J; Tenorio MT; Burgos FJ; Ortuño J
Nephrol Dial Transplant; 2005 Apr; 20(4):803-10. PubMed ID: 15687111
[TBL] [Abstract][Full Text] [Related]
20. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
